Verification evidence is still being completed.
PDF / print export
Gain Therapeutics SA
Lugano, Switzerland
- Verified lead
- Gene Mack
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- President and Chief Executive Officer
- 2026 technical specialization
- Allosteric Small-Molecule Therapeutics, Rare Disease, and Neurodegenerative Clinical Development
- Review cycle
- 24 April 2026
- Full address
- Via Francesco Soave 6, 6900 Lugano, Switzerland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Gain Therapeutics About Us page naming Gene Mack as President and CEO since April 2024.
- Editorial note
- Lugano Nasdaq-listed (GANX) rare-disease biotech with named CEO, dual-site Lugano and Bethesda operations, and an allosteric small-molecule pipeline.
Allosteric Small-Molecule Therapeutics, Rare Disease, and Neurodegenerative Clinical Development
Nasdaq GANX listing, Public CEO disclosure, Swissmedic oversight
Lugano Nasdaq-listed (GANX) rare-disease biotech with named CEO, dual-site Lugano and Bethesda operations, and an allosteric small-molecule pipeline.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Lugano, Switzerland
Gain Therapeutics SA
Allosteric Small-Molecule Therapeutics, Rare Disease, and Neurodegenerative Clinical Development · Clinical-stage small-molecule development
Lugano Nasdaq-listed (GANX) rare-disease biotech with named CEO, dual-site Lugano and Bethesda operations, and an allosteric small-molecule pipeline.
- Lead
- Gene Mack (verified ↗)
- Address
- Via Francesco Soave 6, 6900 Lugano, Switzerland (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Clinical-stage small-molecule development
- Capabilities
- Allosteric Small-Molecule Discovery · Rare and Neurodegenerative Disease Programs · Dual-Site Lugano and Bethesda Operations
- Founded
- 2017
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Gene Mack
President and Chief Executive Officer
Full addressVia Francesco Soave 6, 6900 Lugano, Switzerland
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
Gain Therapeutics Contact Us page listing Via Francesco Soave 6, Lugano.
Open sourceClinical-stage small-molecule development
Lugano, Switzerland. Allosteric Small-Molecule Therapeutics, Rare Disease, and Neurodegenerative Clinical Development. Review completed on 24 Apr 2026.
Swissmedic, FDA, and EMA for clinical oversight
Nasdaq GANX listing, Public CEO disclosure, Swissmedic oversight
Allosteric Small-Molecule Therapeutics, Rare Disease, and Neurodegenerative Clinical Development
Lugano Nasdaq-listed (GANX) rare-disease biotech with named CEO, dual-site Lugano and Bethesda operations, and an allosteric small-molecule pipeline.
Editorial note
Gain Therapeutics combines a Lugano operating headquarters with a Bethesda, MD US office, a named CEO since April 2024, and a Nasdaq listing (GANX) supporting its allosteric small-molecule pipeline for rare diseases.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Allosteric Small-Molecule Discovery
Rare and Neurodegenerative Disease Programs
Dual-Site Lugano and Bethesda Operations
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Allosteric drug-discovery platform
Clinical trial operations
Dual-site Lugano and Bethesda infrastructure
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Gain Therapeutics SA located?
- Gain Therapeutics SA operates from Via Francesco Soave 6, 6900 Lugano, Switzerland, Lugano, Switzerland.
- Who runs Gain Therapeutics SA?
- Gain Therapeutics SA is led by Gene Mack, President and Chief Executive Officer. Verified 24 Apr 2026.
- What does Gain Therapeutics SA do?
- Lugano Nasdaq-listed (GANX) rare-disease biotech with named CEO, dual-site Lugano and Bethesda operations, and an allosteric small-molecule pipeline. Core capabilities: Allosteric Small-Molecule Discovery, Rare and Neurodegenerative Disease Programs, Dual-Site Lugano and Bethesda Operations.
Editorial context
Related technical briefs
Briefs that name Lugano as a covered market or city.